Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental virus injection targets Hard-to-Treat cancers in new trial

NCT ID NCT04370587

Recruiting now Disease control Sponsor: ImmVira Pharma Co. Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new treatment called T3011, a modified virus injected directly into tumors, for people with advanced solid cancers like melanoma, lung cancer, or sarcoma. The study will also test T3011 combined with the immunotherapy drug pembrolizumab (Keytruda). About 30 participants will receive the treatment to check its safety and see if it shrinks tumors. The goal is to find a dose that is safe and potentially effective for further testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
T3011 (a modified virus injected into tumors) and pembrolizumab (an immunotherapy drug given intravenously)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is an early-phase trial with only 30 participants, so safety and effectiveness are not yet proven. The virus injection may cause side effects like inflammation or flu-like symptoms, and the combination with pembrolizumab could increase immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma melanoma metastatic malignant neoplasm non-small cell lung carcinoma sarcoma skin squamous cell carcinoma squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HNSCC MELANOMA NSCLC SARCOMA SOLID TUMOR SQUAMOUS CELL CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Banner MD Anderson Cancer Center

    COMPLETED

    Gilbert, Arizona, 85234, United States

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Email: •••••@•••••

  • Mary Crowley Cancer Research

    RECRUITING

    Dallas, Texas, 75230, United States

    Contact Email: •••••@•••••

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Email: •••••@•••••

  • Peninsula & South Eastern Haematology and Oncology Group

    RECRUITING

    Frankston, Australia

    Contact Email: •••••@•••••

  • Southern Oncology

    RECRUITING

    Bedford Park, Australia

    Contact Email: •••••@•••••

  • The Alfred

    RECRUITING

    Melbourne, Australia

    Contact Email: •••••@•••••

  • University of Pittsburgh Medical Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

    Contact Email: •••••@•••••

  • Virginia Cancer Specialists

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.